Up and Coming

Up and Coming from Assembly, EarlySign and Noveome

November 4, 2019

This feature highlights changes in clinical research organizations’ personnel.

Shantanu Nundy has been appointed chief medical officer at Accolade. Nundy, a practicing physician, was formerly a senior technology advisor in the World Bank Group’s health, nutrition and population global practice.

Cari Kniola has been appointed director of corporate strategy at Aperio Clinical Outcomes. Kniola was most recently senior project manager with the company.

Assembly Biosciences, Inc. named Thomas J. Russo chief financial officer. Russo is the former vice president, head of commercial finance at Gilead Sciences.

Bicycle Therapeutics has named Nigel Crockett chief business officer. Crockett most recently served as a founding partner at Tukan Partners, Ltd.

Andrew Gornell Ballou has been named vice president of investor relations at BioSig Technologies Inc. Ballou was previously managing director, head of institutional equity sales at Janney Montgomery Scott LLC.

Blink Health
Blink Health has named Kathy Reardon chief healthcare counsel. Reardon was most recently chief ethics officer at Cigna.

Boundless Bio
Boundless Bio has appointed Christian Hassig chief scientific officer. Hassig last served as CSO at Sierra Oncology.

John Winstel has been appointed chief accounting officer at DaVita Inc. Winstel previously served as vice president and corporate controller for Cooper Tire & Rubber Company.

EarlySign has named Jeremy Orr chief executive officer. Orr most recently served as chief medical officer with the company.

Judith R. Abrams has been named chief medical officer at Editas Medicine, Inc. Abrams previously served as franchise lead, immunology and neurology, global drug safety innovation at EMD Serono Research and Development Institute, Inc.

Glenn S. Vraniak has been named chief financial officer at Evaxion Biotech. Vraniak was previously CFO of electroCore, Inc.

IVERIC bio, Inc. has named Abraham Scaria chief scientific officer. Scaria formerly served as vice president and head of ophthalmology at Casebia Therapeutics.

Douglas Bain has been named chief technology officer at Boston-based KCR. Bain is the former founder and chief technology officer at eClinicalHealth Ltd.

Dan McCormick has been appointed senior vice president, biopharma practice at Kineticos Life Sciences. McCormick was most recently at Generis Global Solutions as managing director.

Kronos Bio, Inc. has expanded its senior management team with the appointment of Christopher Lee as vice president, program management and Charles Lin as vice president, biology. Lee was most recently senior director, research portfolio management at Gilead Sciences. Lin was previously an assistant professor in the department of molecular and human genetics at Baylor College of Medicine.

Marinus Pharmaceuticals, Inc. has named Joe Hulihan chief medical officer. Hulihan recently served as principal at Paradigm Neuroscience.

NGM Biopharmaceuticals, Inc. has appointed Valerie Pierce as senior vice president, general counsel and chief compliance officer. Pierce was most recently senior vice president, associate general counsel at Jazz Pharmaceuticals.

Kevin E. McCracken has been named senior vice president of operations at Noveome Biotherapeutics, Inc. McCracken was previously vice president of chemistry, manufacturing and controls at Kadmon Pharmaceuticals.

Nuventra Pharma Sciences has named Iftekhar Mahmood senior consultant, clinical pharmacology and pharmacometrics. Mahmood previously served as a clinical pharmacologist at the FDA for over 25 years.

Jessica Crespo has been appointed controller at Ocugen, Inc. Crespo previously held the position of director, accounting/finance at Aerie Pharmaceuticals.

Prometheus Biosciences
Prometheus Biosciences, Inc. has expanded its leadership team with the addition of Chris Slavinsky as general counsel and head of business development and Mike Walther as chief commercial officer. Slavinsky previously served as vice president of the Takeda center for external innovation and head of gastroenterology business development, externalization and special projects; Walther is the former general manager of Aries Pharmaceuticals.

Riverpoint Medical
Doug J. King has been named chief executive officer at Riverpoint Medical. King was formerly president of Medtronic’s spinal business within Medtronic’s restorative therapies group.

Roche Diagnostics
Roche Diagnostics Corporation has named Matthew Sause president and chief executive officer. Sause was most recently senior vice president and head of global commercial product strategy at Gilead Sciences.

David Swetlow has been named chief financial officer at Sernova Corp. Swetlow is the owner of BlueWave Ventures.

Sonde Health
David Liu has been appointed chief executive officer at Sonde Health Inc. Liu was most recently president and chief operating officer at Quartet.

Third Pole
Bill Athenson was named chief executive officer, Elizabeth Holmberg was appointed chief financial officer and Christopher Miles as chief technology officer at Third Pole Therapeutics. Athenson previously held the position of CEO at Three Lakes Partners; Holmberg is the former CFO of Ikaria; Miles was most recently global head of consulting services at Altran.

Tris Pharma
Tris Pharma, Inc. has named Jonathan N. Provoost general counsel. Provoost was previously general counsel for business development and licensing at Mallinckrodt Pharmaceuticals.

Varian, Inc. has named Anshul Maheshwari president of investor relations. Maheshwari is currently vice president and treasurer of the company.

YPrime has named Terek Peterson vice president of clinical analytics and data strategies; Celeste Elash has been appointed director of eCOA sciences. Peterson most recently was senior director of global statistical standards with Covance. Elash was previously an independent COA and eCOA consultant.